Patient-derived tumor-infiltrating lymphocytes expanded ex vivo and infused after preparative chemotherapy; mediate tumor antigen-specific cytotoxicity via TCR recognition to repopulate with highly tumor-reactive T cells.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are infused after lymphodepleting chemotherapy; they recognize tumor antigens via native TCRs and mediate antigen-specific cytotoxicity, persisting and expanding in vivo to repopulate with highly tumor-reactive T cells.
Infused autologous TILs recognize tumor antigen peptide–HLA class I complexes via their native TCRs and directly kill target cells through perforin/granzyme release and Fas–FasL–mediated apoptosis.
Patient-derived tumor-infiltrating lymphocytes expanded ex vivo and infused after preparative chemotherapy; mediate tumor antigen-specific cytotoxicity via TCR recognition to repopulate with highly tumor-reactive T cells.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are infused after lymphodepleting chemotherapy; they recognize tumor antigens via native TCRs and mediate antigen-specific cytotoxicity, persisting and expanding in vivo to repopulate with highly tumor-reactive T cells.
TILs recognize the tumor antigenic peptide–HLA-B complex via their native TCRs and directly kill target cells by perforin/granzyme release and Fas–FasL–mediated apoptosis.
Patient-derived tumor-infiltrating lymphocytes expanded ex vivo and infused after preparative chemotherapy; mediate tumor antigen-specific cytotoxicity via TCR recognition to repopulate with highly tumor-reactive T cells.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are infused after lymphodepleting chemotherapy; they recognize tumor antigens via native TCRs and mediate antigen-specific cytotoxicity, persisting and expanding in vivo to repopulate with highly tumor-reactive T cells.
TILs recognize the tumor antigenic peptide–HLA-C complex via native TCRs and kill target cells through cytotoxic T-cell effector mechanisms (perforin/granzyme and Fas–FasL), with proinflammatory cytokines aiding apoptosis.
Patient-derived tumor-infiltrating lymphocytes expanded ex vivo and infused after preparative chemotherapy; mediate tumor antigen-specific cytotoxicity via TCR recognition to repopulate with highly tumor-reactive T cells.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are infused after lymphodepleting chemotherapy; they recognize tumor antigens via native TCRs and mediate antigen-specific cytotoxicity, persisting and expanding in vivo to repopulate with highly tumor-reactive T cells.
TILs with native TCRs recognize the tumor antigenic peptide–HLA-DR (class II pMHC) on target cells and directly kill them via perforin/granzyme release and/or Fas–FasL–mediated apoptosis.
Patient-derived tumor-infiltrating lymphocytes expanded ex vivo and infused after preparative chemotherapy; mediate tumor antigen-specific cytotoxicity via TCR recognition to repopulate with highly tumor-reactive T cells.
Autologous tumor-infiltrating lymphocytes expanded ex vivo are infused after lymphodepleting chemotherapy; they recognize tumor antigens via native TCRs and mediate antigen-specific cytotoxicity, persisting and expanding in vivo to repopulate with highly tumor-reactive T cells.
TILs recognize the tumor antigenic peptide–HLA-DQ complex via their native TCRs and directly kill the bound cell through perforin/granzyme-mediated cytolysis (and Fas–FasL apoptosis).